Novo Nordisk is taking aim at Eli Lilly with a new obesity drug deal. Meanwhile, a survey shows doctors’ perception of the ...
Pharmaceutical Technology on MSN13h
Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shotNovo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback